Biocept (BIOC) – Analysts’ Weekly Ratings Changes

Biocept (NASDAQ: BIOC) has recently received a number of price target changes and ratings updates:

  • 1/22/2023 – Biocept is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 1/14/2023 – Biocept is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 1/6/2023 – Biocept was downgraded by analysts at Brookline Capital Management from a “buy” rating to a “hold” rating.
  • 1/6/2023 – Biocept is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 12/29/2022 – Biocept is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 12/21/2022 – Biocept is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 12/13/2022 – Biocept is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 12/5/2022 – Biocept is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 11/27/2022 – Biocept is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

Biocept Stock Up 2.8 %

Shares of NASDAQ BIOC opened at $0.60 on Tuesday. The firm has a market cap of $10.19 million, a PE ratio of -0.61 and a beta of 0.82. Biocept, Inc. has a 12-month low of $0.46 and a 12-month high of $3.06. The company’s fifty day simple moving average is $0.64 and its 200 day simple moving average is $0.82. The company has a quick ratio of 4.86, a current ratio of 5.13 and a debt-to-equity ratio of 0.04.

Biocept (NASDAQ:BIOCGet Rating) last issued its earnings results on Thursday, November 10th. The medical research company reported ($0.31) earnings per share (EPS) for the quarter. The company had revenue of $10.61 million for the quarter. Biocept had a negative return on equity of 49.18% and a negative net margin of 32.99%. As a group, sell-side analysts forecast that Biocept, Inc. will post -1.02 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Biocept stock. Millennium Management LLC acquired a new stake in Biocept, Inc. (NASDAQ:BIOCGet Rating) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 103,124 shares of the medical research company’s stock, valued at approximately $97,000. Millennium Management LLC owned approximately 0.61% of Biocept at the end of the most recent quarter. Institutional investors own 10.04% of the company’s stock.

Biocept, Inc is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample.

Featured Stories

Receive News & Ratings for Biocept Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept Inc and related companies with MarketBeat.com's FREE daily email newsletter.